Notification from the General Office of the National Medical Products Administration on the Second Phase of the Pilot Program for Personalized Cosmetics Services
Drug Supervision Comprehensive Office No. 58, 2025

Issued on: September 17, 2025

To the Drug Supervision and Administration Bureaus of Beijing, Tianjin, Hebei, Heilongjiang, Shanghai, Zhejiang, Shandong, Henan, Hunan, Guangdong, Guangxi, Hainan, Chongqing, Yunnan, and Shaanxi:

To further deepen the reform of cosmetic supervision, meet the personalized and diversified needs of consumers for cosmetics, explore feasible models and effective supervision measures for personalized cosmetic services, and promote high-quality development of the cosmetics industry, the National Medical Products Administration (NMPA) has decided to launch the second phase of the pilot program for personalized cosmetics services in certain regions based on the summary of previous pilot work. The following matters are hereby notified:

1. Effective from October 1, 2025, cosmetic registrants or domestic responsible persons authorized by foreign registrants participating in the pilot program can, at their established specialty stores, directly-operated stores, or other business locations, provide on-site services including small-scale simple blending and repackaging of two or more registered ordinary cosmetics based on consumers' personalized needs. The pilot program will last for two years.

2. The personalized service pilot program should adhere to the principles of "demand-driven, safety-controlled, and standardized," in accordance with the "Requirements for the Pilot Program of Personalized Cosmetics Services" (see attachment). Provincial-level drug supervision and administration departments participating in the pilot should, based on the actual situation of their administrative regions, develop pilot implementation plans, strictly control the scale of the pilot, and select cosmetic registrants or domestic responsible persons with good social credit, complete quality management systems, and certain work foundation and technical reserves.

3. The cosmetic registrants or domestic responsible persons participating in the pilot program should incorporate the business locations providing personalized services into their quality management systems, and establish management systems to ensure the quality and safety of personalized service products. The use of intelligent equipment and technology to provide personalized services to consumers is encouraged.

4. Provincial-level drug supervision and administration departments participating in the pilot should actively explore innovative models for personalized service pilots, establish a full-process supervision system for personalized services, effectively prevent quality and safety risks, and timely address challenges encountered in the pilot program. Major issues should be reported to the National Medical Products Administration in a timely manner.

5. The National Medical Products Administration will strengthen guidance and supervision of the pilot program, establish a communication mechanism for the pilot work, and adjust the pilot scope as needed based on the progress. If problems are found, the participating provincial-level drug supervision and administration departments must rectify them in a timely manner. If corrections are not made as required, the pilot program will be suspended.